/Investor DB

HealthQuest Capital — 2016 Investments

3 investments dated 2016 · listed companies and verified rows first · show all

NextCurenextcure.comNASDAQ: NXTCSeries A · Jan 2016 · $67M

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+4 more

bioTheranosticsbiotheranostics.cominJan 2016

Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology.

BiotechHealthtechMedical DevicesSan Diego, US

Nicholas Barthelemy(Executive Officer, Director, Promoter)

BoardDavid Kabakoff(Director)inEric Bednarski(Director)Alejandro Sanchez(Director)in

Co-investorsEvidity Health CapitalMVM Life Science Partners

Spiroxspiroxmed.comMar 2016

Menlo Park, US

Duke Rohlen(Chief Executive Officer)

BoardCamille Samuels(Director)Anthony Natale(Director)inReed Gaither(Director)Aftab Kherani(Director)Ron Kuppersmith(Director)

Co-investorsAisling CapitalAPERTURE Venture PartnersCorrelation VenturesVenrockWestern Technology Investment

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.